Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

Canada NewsWire May 7, 2013

Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013

Canada NewsWire May 1, 2013

Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013

PR Newswire May 1, 2013

Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

Canada NewsWire April 23, 2013

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

Canada NewsWire April 17, 2013

David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.

Canada NewsWire April 15, 2013

Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

Canada NewsWire April 10, 2013

Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer

Canada NewsWire April 10, 2013

Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

Canada NewsWire April 3, 2013

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results

Canada NewsWire March 21, 2013

FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing

Marketwired March 13, 2013

Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

Canada NewsWire March 13, 2013

Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

PR Newswire March 13, 2013

Zynga Shares Rise on Yahoo Buyout Speculation. Can the Market Keep Up the 7 Day Bull Rally?

PR Newswire March 12, 2013

Free Research Reports on AEZS, AMPE, ELN and MDCO Issued by the Bedford Report

Marketwired March 12, 2013

Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013

Canada NewsWire March 12, 2013

IIROC Trade Resumption - AEZ (all issues)

Canada NewsWire March 11, 2013

IIROC Trade Resumption - Aeterna Zentaris Inc.

Newsfile March 11, 2013

IIROC Trading Halt - AEZ

Canada NewsWire March 11, 2013

IIROC Trade Halt - Aeterna Zentaris Inc.

Newsfile March 11, 2013